Squalene synthase inhibitors suppress triglyceride biosynthesis through the farnesol pathway in rat hepatocytes

Journal of Lipid Research

Volumn 44, Issue 1, 2003, Pages 128-135

  Hiyoshi, Hironobu ^a   Yanagimachi, Mamoru ^a   Ito, Masashi ^a   Yasuda, Nobuyuki ^a   Okada, Toshimi ^a   Ikuta, Hironori ^a   Shinmyo, Daisuke ^a   Tanaka, Keigo ^a   Kurusu, Nobuyuki ^a   Yoshida, Ichiro ^a   Abe, Shinya ^a   Saeki, Takao ^a   Tanaka, Hiroshi ^a  

^a EISAI CO LTD   (Japan)

Author keywords

ER 27856; HMG CoA reductase; Isoprenoid pathway; RPR 107393; Squalene epoxidase

Indexed keywords

3 [(3,3' BITHIOPHEN 5 YL)METHOXY] N (6,6 DIMETHYL 2 HEPTEN 4 YNYL) N ETHYLBENZYLAMINE; ACETIC ACID; ATORVASTATIN; CARBON 14; CELL PROTEIN; CHOLESTEROL; ER 27856; FATTY ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOPRENOID; OLEIC ACID; PALMITIC ACID; RPR 107393; SQUALENE MONOOXYGENASE; SQUALENE SYNTHASE INHIBITOR; TRIACYLGLYCEROL; TRITIUM; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BIOSYNTHESIS; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INHIBITION; FATTY ACID SYNTHESIS; LIVER CELL; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONTENT; RAT;

ANIMALS; BENZYLAMINES; CELLS, CULTURED; CHOLESTEROL; ENZYME INHIBITORS; FARNESOL; FARNESYL-DIPHOSPHATE FARNESYLTRANSFERASE; HEPATOCYTES; HEPTANOIC ACIDS; LIPID METABOLISM; MALE; OXIDATION-REDUCTION; PYRROLES; RATS; RATS, SPRAGUE-DAWLEY; THIOPHENES; TRIGLYCERIDES;

EID: 0037243080     PISSN: 00222275     EISSN: None     Source Type: Journal    
DOI: 10.1194/jlr.M200316-JLR200     Document Type: Article

References (56)

1. Goldstein, J. L., and M. S. Brown. 1990. Regulation of the mevalonate pathway. Nature. 343: 425-430.
2. Biller, S. A., K. Neuenschwander, M. M. Ponpipom, and C. D. Poulter. 1996. Squalene synthase inhibitors. Curr. Pharm. Des. 2: 1-40.
3. Fung, A. K., W. R. Baker, S. Fakhoury, H. H. Stein, J. Cohen, B. G. Donner, D. S. Garvey, K. P. Spina, and S. H. Rosenberg. 1997. (1 alpha, 2 beta, 3 beta, 4 alpha)-1,2-bis[N-propyl-N-(4-phenoxybenzyl)amino] carbonyl]cyclobutane-3,4-dicarboxylic acid (A-87049): a novel potent squalene synthase inhibitor. J. Med. Chem. 40: 2123-2125.
4. Amin, D., R. Z. Rutledge, S. N. Needle, H. E. Galczenski, K. Neuenschwander, A. C. Scotese, M. P. Maguire, R. C. Bush, D. J. Hele, G. E. Bilder, and M. H. Perrone. 1997. RPR 107393, a potent squalene synthase inhibitor and orally effective cholesterol-lowering agent: comparison with inhibitors of HMG-CoA reductase. J. Pharmacol. Exp. Ther. 281: 746-752.
5. Ugawa, T., H. Kakuta, H. Moritani, K. Matsuda, T. Ishihara, M. Yamaguchi, S. Naganuma, Y. Iizumi, and H. Shikama. 2000. YM-53601, a novel squalene synthase inhibitor, reduces plasma cholesterol and triglyceride levels in several animal species. Br. J. Pharmacol. 131: 63-70.
6. Hiyoshi, H., M. Yanagimachi, M. Ito, I. Ohtsuka, I. Yoshida, T. Saeki, and H. Tanaka. 2000. Effect of ER-27856, a novel squalene synthase inhibitor, on plasma cholesterol in rhesus monkeys: comparison with 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors. J. Lipid Res. 41: 1136-1144.
7. Hiyoshi, H., M. Yanagimachi, M. Ito, T. Saeki, I. Yoshida, T. Okada, H. Ikuta, D. Shinmyo, K. Tanaka, N. Kurusu, and H. Tanaka. 2001. Squalene synthase inhibitors reduce plasma triglyceride through a low-density lipoprotein receptor-independent mechanism. Eur. J. Pharmacol. 431: 345-352.
8. Jeppesen, J., H. O. Hein, P. Suadicani, and F. Gyntelberg. 1998. Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study. Circulation. 97: 1029-1036.
9. Sprecher, D. L. 1998. Triglycerides as a risk factor for coronary artery disease. Am. J. Cardiol. 82: 49U-56U.
10. Austin, M. A., J. E. Hokanson, and K. L. Edwards. 1998. Hypertriglyceridemia as a cardiovascular risk factor. Am. J. Cardiol. 81: 7B-12B.
11. Miller, M., A. Seidler, A. Moalemi, and T. A. Pearson. 1998. Normal triglyceride levels and coronary artery disease events: the Baltimore Coronary Observational Long-Term Study. J. Am. Coll. Cardiol. 31: 1252-1257.
12. Bilheimer, D. W., S. M. Grundy, M. S. Brown, and J. L. Goldstein. 1983. Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholesterolemia heterozygotes. Proc. Natl. Acad. Sci. USA. 80: 4124-4128.
13. Grundy, S. M., and G. L. Vega. 1985. Influence of mevinolin on metabolism of low density lipoproteins in primary moderate hypercholesterolemia. J. Lipid Res. 26: 1464-1475.
14. Ginsberg, H. N., N. A. Le, M. P. Short, R. Ramakrishnan, and R.J. Desnick. 1987. Suppression of apolipoprotein B production during treatment of cholesteryl ester storage disease with lovastatin. Implications for regulation of apolipoprotein B synthesis. J. Clin. Invest. 80: 1692-1697.
15. Arad, Y., R. Ramakrishnan, and H. N. Ginsberg. 1990. Lovastatin therapy reduces low density lipoprotein apoB levels in subjects with combined hyperlipidemia by reducing the production of apoB-containing lipoproteins: implications for the pathophysiology of apoB production. J. Lipid Res. 31: 567-582.
16. Reihner, E., M. Rudling, D. Stahlberg, L. Berglund, S. Ewerth, I. Bjorkhem, K. Einarsson, and B. Angelin. 1990. Influence of pravastatin, a specific inhibitor of HMG-CoA reductase, on hepatic metabolism of cholesterol. N. Engl. J. Med. 323: 224-228.
17. Bergstrom, J. D., M. M. Kurtz, D. J. Rew, A. M. Amend, J. D. Karkas, R. G. Bostedor, V. S. Bansal, C. Dufresne, E. L. VanMiddlesworth, O. D. Hensens, J. M. Liesch, D. L. Zink, K. E. Wilson, J. Onishi, J. A. Milligan, G. Bills, L. Kaplan, M. Nallin Omstead, R. G. Jenkins, L. Huang, M. S. Meinz, L. Quinn, R. W. Burg, Y. L. Kong, S. Mochales, M. Mojena, I. Martin, F. Pelaez, M. T. Diez, and A. W. Alberts. 1993. Zaragozic acids: a family of fungal metabolites that are picomolar competitive inhibitors of squalene synthase. Proc. Natl. Acad. Sci. USA. 90: 80-84.
18. Keller, R. K. 1996. Squalene synthase inhibition alters metabolism of nonsterols in rat liver. Biochim. Biophys. Acta. 1303: 169-179.
19. Vaidya, S., R. Bostedor, M. M. Kurtz, J. D. Bergstrom, and V. S. Bansal. 1998. Massive production of farnesol-derived dicarboxylic acids in mice treated with the squalene synthase inhibitor zaragozic acid A. Arch. Biochem. Biophys. 355: 84-92.
20. Bostedor, R. G., J. D. Karkas, B. H. Arison, V. S. Bansal, S. Vaidya, J. I. Germershausen, M. M. Kurtz, and J. D. Bergstrom. 1997. Farnesol-derived dicarboxylic acids in the urine of animals treated with zaragozic acid A or with farnesol. J. Biol. Chem. 272: 9197-9203.
21. Bansal, V. S., and S. Vaidya. 1994. Characterization of two distinct allyl pyrophosphatase activities from rat liver microsomes. Arch. Biochem. Biophys. 315: 393-399.
22. Melnykovych, G., J. S. Haug, and C. M. Goldner. 1992. Growth inhibition of leukemia cell line CEM-C1 by farnesol: effects of phosphatidylcholine and diacylglycerol. Biochem. Biophys. Res. Commun. 186: 543-548.
23. Burke, Y. D., M. J. Stark, S. L. Roach, S. E. Sen, and P. L. Crowell. 1997. Inhibition of pancreatic cancer growth by the dietary isoprenoids farnesol and geraniol. Lipids. 32: 151-156.
24. Voziyan, P. A., J. S. Haug, and G. Melnykovych. 1995. Mechanism of farnesol cytotoxicity: further evidence for the role of PKCdependent signal transduction in farnesol-induced apoptotic cell death. Biochem. Biophys. Res. Commun. 212: 479-486.
25. Rioja, A., A. R. Pizzey, C. M. Marson, and N. S. Thomas. 2000. Preferential induction of apoptosis of leukaemic cells by farnesol. FEBS Lett. 467: 291-295.
26. Roullet, J. B., H. Xue, J. Chapman, P. McDougal, C. M. Roullet, and D. A. McCarron. 1996. Farnesyl analogues inhibit vasoconstriction in animal and human arteries. J. Clin. Invest. 97: 2384-2390.
27. 2+ channels in vascular smooth muscle cells. J. Biol. Chem. 272: 32240-32246.
28. 2+ channel by targeting the alpha 1C subunit. Arterioscler. Thromb. Vasc. Biol. 19: 959-966.
29. Bradfute, D. L., and R. D. Simoni. 1994. Non-sterol compounds that regulate cholesterogenesis. Analogues of farnesyl pyrophosphate reduce 3-hydroxy-3-methylglutaryl-coenzyme A reductase levels. J. Biol. Chem. 269: 6645-6650.
30. Correll, C. C., L. Ng, and P. A. Edwards. 1994. Identification of farnesol as the non-sterol derivative of mevalonic acid required for the accelerated degradation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. J. Biol. Chem. 269: 17390-17393.
31. Meigs, T. E., D. S. Roseman, and R. D. Simoni. 1996. Regulation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase degradation by the nonsterol mevalonate metabolite farnesol in vivo. J. Biol. Chem. 271: 7916-7922.
32. Meigs, T. E., and R. D. Simoni. 1997. Farnesol as a regulator of HMG-CoA reductase degradation: characterization and role of farnesyl pyrophosphatase. Arch. Biochem. Biophys. 345: 1-9.
33. Forman, B. M., E. Goode, J. Chen, A. E. Oro, D. J. Bradley, T. Perimann, D. J. Noonan, L. T. Burka, T. McMorris, W. W. Lamph, R. M. Evans, and C. Weinberger. 1995. Identification of a nuclear receptor that is activated by farnesol metabolites. Cell. 81: 687-693.
34. Hanley, K., L. G. Komuves, D. C. Ng, Y. Schoonjans, S. S. He, P. Lau, D. D. Bikle, M. L. Williams, P. M. Elias, J. Auwerx, and K. R. Feingold. 2000. Farnesol stimulates differentiation in epidermal keratinocytes via PPARalpha. J. Biol. Chem. 275: 11484-11491.
35. Brower, P. L., D. E. Butler, C. F. Deering, T. V. Le, A. Millar, T. N. Nanninga, and B. D. Roth. 1992. The synthesis of (4R-cis)-1,1-dimethylethyl-6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate, a key intermediate for the preparation of CI-981, a highly potent, tissue selective inhibitor of HMG-CoA reductase. Tetrahedron Lett. 33: 2279-2282.
36. Baumann, K. L., D. E. Buder, C. F. Deering, K. E. Mennen, A. Millar, T. N. Nanninga, C. W. Palmer, and B. D. Roth. 1992. The convergent synthesis of CI-981, an optically active, highly potent, tissue selective inhibitor of HMG-CoA reductase. Tetrahedron Lett. 33: 2283-2284.
37. Moldeus, P., J. Hogberg, and S. Orrenius. 1978. Isolation and use of liver cells. Methods Enzymol. 52: 60-71.
38. Lee, Y., H. Hirose, Y. T. Zhou, V. Esser, J. D. McGarry, and R. H. Unger. 1997. Increased lipogenic capacity of the islets of obese rats: a role in the pathogenesis of NIDDM. Diabetes. 46: 408-413.
39. Spurway, T. D., C. I. Pogson, H. S. Sherratt, and L. Agius. 1997. Etomoxir, sodium 2-[6-(4-chlorophenoxy)hexyl] oxirane-2-carboxylate, inhibits triacylglycerol depletion in hepatocytes and lipolysis in adipocytes. FEBS Lett. 404: 11-14.
40. Ribeiro, A., M. Mangeney, C. Loriette, G. Thomas, D. Pepin, B. Janvier, J. Chambaz, and G. Bereziat. 1991. Effect of simvastatin on the synthesis and secretion of lipoproteins in relation to the metabolism of cholesterol in cultured hepatocytes. Biochim. Biophys. Acta. 1086: 279-286.
41. Funatsu, T., K. Suzuki, M. Goto, Y. Arai, H. Kakuta, H. Tanaka, S. Yasuda, M. Ida, S. Nishijima, and K. Miyata. 2001. Prolonged inhibition of cholesterol synthesis by atorvastatin inhibits apo B-100 and triglyceride secretion from HepG2 cells. Atherosclerosis. 157: 107-115.
42. Ooyen, C., A. Zecca, A. M. Bersino, and A. L. Catapano. 1999. NKI04, a potent 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, decreases apolipoprotein B-100 secretion from Hep G2 cells. Atherosclerosis. 145: 87-95.
43. Horie, M., Y. Tsuchiya, M. Hayashi, Y. Iida, Y. Iwasawa, Y. Nagata, Y. Sawasaki, H. Fukuzumi, K. Kitani, and T. Kamei. 1990. NB-598: a potent competitive inhibitor of squalene epoxidase. J. Biol. Chem. 265: 18075-18078.
44. Horie, M., Y. Iwasawa, T. Satoh, A. Shimizu, Y. Nagata, and T. Kamei. 1993. Effects of NB-598, a potent squalene epoxidase inhibitor, on the apical membrane uptake of cholesterol and basolateral membrane secretion of lipids in Caco-2 cells. Biochem. Pharmacol. 46: 297-305.
45. Kerner, J., and C. Hoppel. 2000. Fatty acid import into mitochondria. Biochim. Biophys. Acta. 1486: 1-17.
46. Bennett, M. K., J. M. Lopez, H. B. Sanchez, and T. F. Osborne. 1995. Sterol regulation of fatty acid synthase promoter. Coordinate feedback regulation of two major lipid pathways. J. Biol. Chem. 270: 25578-25583.
47. Lopez, J. M., M. K. Bennett, H. B. Sanchez, J. M. Rosenfeld, and T. E. Osborne. 1996. Sterol regulation of acetyl coenzyme A carboxylase: a mechanism for coordinate control of cellular lipid. Proc. Natl. Acad. Sci. USA. 93: 1049-1053.
48. Tabor, D. E., J. B. Kim, B. M. Spiegelman, and P. A. Edwards. 1999. Identification of conserved cis-elements and transcription factors required for sterol-regulated transcription of stearoyl-CoA desaturase 1 and 2. J. Biol. Chem. 274: 20603-20610.
49. Shimano, H., N. Yahagi, M. Amemiya-Kudo, A. H. Hasty, J. Osuga, Y. Tamura, F. Shionoiri, Y. Iizuka, K. Ohashi, K. Harada, T. Gotoda, S. Ishibashi, and N. Yamada. 1999. Sterol regulatory element-binding protein-1 as a key transcription factor for nutritional induction of lipogenic enzyme genes. J. Biol. Chem. 274: 35832-35839.
50. Hardie, D. G. 1992. Regulation of fatty acid and cholesterol metabolism by the AMP-activated protein kinase. Biochim. Biophys. Acta. 1123: 231-238.
51. Gaussin, V., P. Skarlas, Y. P. Ching, D. G. Hardie, and L. Hue. 1997. Distinct type-2A protein phosphatases activate HMGCoA reductase and acetyl-CoA carboxylase in liver. FEBS Lett. 413: 115-118.
52. Hillgartner, F. B., L. M. Salati, and A. G. Goodridge. 1995. Physiological and molecular mechanisms involved in nutritional regulation of fatty acid synthesis. Physiol. Rev. 75: 47-76.
53. Boone, A. N., A. Chan, J. E. Kulpa, and R. W. Brownsey. 2000. Bimodal activation of acetyl-CoA carboxylase by glutamate. J. Biol. Chem. 275: 10819-10825.
54. Hampton, R. Y., and H. Bhakta. 1997. Ubiquitin-mediated regulation of 3-hydroxy-3-methylglutaryl-CoA reductase. Proc. Natl. Acad. Sci. USA. 94: 12944-12948.
55. Gardner, R. G., and R. Y. Hampton. 1999. A highly conserved signal controls degradation of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase in eukaryotes. J. Biol. Chem. 274: 31671-31678.
56. McGee, T. P., H. H. Cheng, H. Kumagai, S. Omura, and R. D. Simoni. 1996. Degradation of 3-hydroxy-3-methylglutaryl-CoA reductase in endoplasmic reticulum membranes is accelerated as a result of increased susceptibility to proteolysis. J. Biol. Chem. 271: 25630-25638.